Yisa Sunmonu, MD
Sleep Medicine · Ashtabula, OHNPI 1528026531
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,937, more than ten times the $24 reported in 2019.
Across 160 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$560
- AstraZeneca$519
- Regeneron Healthcare Solutions, Inc.$317
- Sanofi$313
- Mylan Specialty L.p.$210
- Amgen$209
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,10496%
- Education$1454%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 35 | $560 |
| AstraZeneca(2 entities) | 26 | $519 |
| Regeneron Healthcare Solutions, Inc. | 11 | $317 |
| Sanofi | 14 | $313 |
| Mylan Specialty L.p. | 9 | $210 |
| Amgen | 13 | $209 |
| Harmony Biosciences LLC | 5 | $204 |
| Abbott | 6 | $114 |
| UCB, Inc. | 3 | $94 |
| Lilly USA, LLC | 4 | $78 |
| Averitas Pharma Inc. | 3 | $77 |
| Insmed, Inc. | 4 | $65 |
| Merck | 2 | $46 |
| Medtronic | 3 | $44 |
| Genentech USA, Inc. | 2 | $41 |
| Viatris Specialty LLC | 2 | $38 |
| Pacira Pharmaceuticals Incorporated | 2 | $33 |
| Boehringer Ingelheim | 2 | $31 |
| Saluda Medical Americas, Inc. | 2 | $30 |
| GRT US Holding, Inc. | 1 | $27 |
| Optinose US, Inc. | 1 | $26 |
| Solventum Corporation | 1 | $23 |
| Stryker | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Vertos Medical, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Pfizer | 1 | $17 |
| Grifols USA, LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Relievant Medsystems, Inc. | 1 | $11 |
How this compares
$3,249 in reported general payments places this provider in the 65th percentile of 94 sleep medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 412 | $333,888 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 237 | $128,291 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 127 | $112,536 |
| Breo ElliptaFluticasone/Vilanterol | 228 | $103,713 |
| Spiriva RespimatTiotropium Bromide | 110 | $81,379 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 89 | $64,621 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 87 | $50,813 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 888 | $21,878 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $19,364 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 30 | $17,996 |
| DuleraMometasone/Formoterol | 32 | $15,704 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $12,117 |
| NuvigilArmodafinil | 11 | $11,838 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 24 | $11,587 |
| Ventolin HfaAlbuterol Sulfate | 146 | $11,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $560 | $578,706909 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $31 | $196,813286 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $519 | $149,896219 claims |
| MerckDulera | $46 | $15,70432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 94 sleep medicine providers in Ohio.
Other sleep medicine in Ashtabula
- Asim RoyDublin$666K
- Shahrokh JavaheriCincinnati$404K
- Louis TartagliaMaumee$314K
- John AndrefskyParma$147K
- Anthony SuchoskiCincinnati$89K
- Nancy Foldvary-SchaeferCleveland$75K
- Shayla PullenCincinnati$71K
- Gautam SamadderColumbus$53K
- Kevin CarterBeavercreek$49K
- Brian ChenCleveland$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.